We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

3 hedge funds and large institutions have $21.7M invested in Decoy Therapeutics in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $18.6M → $21.7M (+$3.06M)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more ownership

Funds ownership: 0% → 0% (0%)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$742K
2
ECM
Element Capital Management
New York
-$57K

DCOY Hedge Fund Activity: Q4 2017 in Review

3 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2017, worth a combined $21.7M — up 16% from $18.6M a quarter earlier.

Fund positioning in DCOY was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Fidelity Investments, cutting an estimated $742K.

  • 3 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $21.7M of Decoy Therapeutics stock for Q4 2017, up 16% quarter-over-quarter.
  • 0 funds opened new Decoy Therapeutics positions in Q4 2017 and 0 closed out.
  • The largest Decoy Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $742K sold.

Based on aggregated 13F filings for Q4 2017.